ArticlePediatric nephrology (Berlin, Germany)2010
Rasburicase improves hyperuricemia in infants with acute kidney injury.
Article in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Hyperuricemia in preterm infants: clinical features and early rasburicase therapy.Pediatric research · 2026Article
- Use of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury.Clinical and experimental nephrology · 2024Article
- Pediatric acute kidney injury: new advances in the last decade.Kidney research and clinical practice · 2021Article
- Hypercalcemia, hyperuricemia, and kidney dysfunction in a 35-month-old boy: Answers.Pediatric nephrology (Berlin, Germany) · 2021Article
- Acute post-streptococcal glomerulonephritis - immune-mediated acute kidney injury - case report and literature review.Central-European journal of immunology · 2021Article
- "Disproportionate" hyperuricemia in children with hemolytic uremic syndrome (HUS): should we regard this as a "medical emergency"?Pediatric nephrology (Berlin, Germany) · 2020Article
- Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.Pediatric nephrology (Berlin, Germany) · 2020Article
- Article
- Cyanosis in a male Nigerian infant with acute kidney injury: answers.Pediatric nephrology (Berlin, Germany) · 2014Article
- Analysis of reference interval and age-related changes in serum biochemistry and hematology in the specific pathogen free miniature pig.Laboratory animal research · 2012Article
- Hyperuricemia in children with post-diarrheal hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2012Article
- Is it the right time to subject children with acute kidney injury to rasburicase trials?Pediatric nephrology (Berlin, Germany) · 2012Article
- Update on acute kidney injury in the neonate.Current opinion in pediatrics · 2012Review
- Rasburicase for hyperuricemia in hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2012Article
- Acute kidney injury: can we improve prognosis?Pediatric nephrology (Berlin, Germany) · 2010Review
- The value of serum uric Acid as a mortality prediction in critically ill children.Iranian journal of pediatrics · 2010Article
- Rasburicase in the treatment of hyperuricemia of newborns.Pediatric nephrology (Berlin, Germany) · 2010Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent data suggest that elevated levels of uric acid (UA) might contribute to the progression of renal disease. Rasburicase, recombinant urate oxidase, is a highly safe and efficacious hypo-uricosuric agent for treatment of elevated UA levels from tumor lysis. We adopted the use of rasburicase for management of hyperuricemia in infants with acute kidney injury (AKI) and, herein, report our experience. We conducted a retrospective chart review of infants with hyperuricemia (UA > 8 mg/dl) secondary to AKI (serum creatinine > 1.5 mg/dl) treated with rasburicase. Seven infants (mean age 34 +/- 55 days, six male), with a mean weight of 3.2 +/- 1.2 kg, were identified. Rasburicase was administered intravenously as a single, onetime, bolus of 0.17 +/- 0.04 mg/kg body weight. Within 24 h, serum UA had decreased from 13.6 +/- 4.5 mg/dl to 0.9 +/- 0.6 mg/dl (P < 0.05), creatinine had decreased from 3.2 +/- 2.0 mg/dl to 2.0 +/- 1.2 mg/dl (P < 0.05), and urinary output had increased from 2.4 +/- 1.2 ml/kg per hour to 5.9 +/- 1.8 ml/kg per hour (P < 0.05). Continued improvements in UA, creatinine, and urinary output were observed in the week following administration of rasburicase, without rebound of the UA. We observed no treatment-related side effects. All patients demonstrated a normalization of uric acid level without need of renal replacement therapy. In conclusion, a single intravenously administered bolus of rasburicase appears to be a novel treatment for hyperuricemia in infants with AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.